A detailed history of Cullen/Frost Bankers, Inc. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 173 shares of JANX stock, worth $8,435. This represents 0.0% of its overall portfolio holdings.

Number of Shares
173
Previous 169 2.37%
Holding current value
$8,435
Previous $7,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$35.29 - $50.26 $141 - $201
4 Added 2.37%
173 $7,000
Q2 2024

Aug 05, 2024

BUY
$35.12 - $64.78 $5,935 - $10,947
169 New
169 $7,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.03B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Cullen/Frost Bankers, Inc. Portfolio

Follow Cullen/Frost Bankers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.